{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:28:47Z","timestamp":1781900927018,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite the growing body of knowledge about TM6SF2 and PNPLA3 polymorphisms in non-alcoholic fatty liver disease, their influence in the spectrum of HCV liver disease is not yet fully defined. Besides that, admixed populations, such as Brazilians, were not included in most of the studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This cross-sectional study enrolled 365 treatment-na\u00efve patients with HCV and 134 healthy individuals. TM6SF2 (rs58542926 c.499C\u2009&gt;\u2009T) and PNPLA3 (rs738409 c.444C\u2009&gt;\u2009G) polymorphisms were evaluated regarding their association with clinical and laboratory data, histological liver steatosis and fibrosis, and with components of the metabolic syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In HCV subjects, the frequencies of TM6SF2 CC and CT\u2009+\u2009TT were 89% and 11%, while PNPLA3 frequencies of CC and CG\u2009+\u2009GG were 51.4% and 48.6%. In the univariate logistic regression analysis, the TM6SF2 CT\u2009+\u2009TT genotype in HCV was associated with significant liver fibrosis (<jats:italic>p<\/jats:italic>\u2009=\u20090.047; OR 1.953; 95% CI 1.009\u20133.788). In comparison to the CT\u2009+\u2009TT genotype, the TM6SF2 CC genotype in HCV was associated with older age (<jats:italic>p<\/jats:italic>\u2009=\u20090.002), higher frequency of arterial hypertension (<jats:italic>p<\/jats:italic>\u2009=\u20090.032), obesity (<jats:italic>p<\/jats:italic>\u2009=\u20090.030), metabolic syndrome (<jats:italic>p<\/jats:italic>\u2009=\u20090.014) and lower total cholesterol levels (<jats:italic>p<\/jats:italic>\u2009=\u20090.036). The PNPLA3 GG subjects had lower body mass index than CG\/ CC individuals (<jats:italic>p<\/jats:italic>\u2009=\u20090.047). None of the polymorphisms, or their combinations, was independently associated with hepatic steatosis or fibrosis. On the other hand, older age, lower serum levels of total cholesterol, and higher serum levels of alanine aminotransferase and alkaline phosphatase were associated with liver fibrosis in the multivariate logistic regression analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this evaluation of an admixed HCV population, neither TM6SF2 nor PNPLA3 polymorphisms were independently associated with hepatic steatosis or fibrosis. Other factors seem more influential than these specific polymorphisms in isolation. More studies are warranted to clarify the role of the TM6SF2 and PNPLA3 polymorphisms in Brazilians with HCV.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-01654-3","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T11:12:59Z","timestamp":1614078779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C"],"prefix":"10.1186","volume":"21","author":[{"given":"Arthur Ivan N.","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda M.","family":"Malta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Momoyo Y.","family":"Zitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula M.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele S.","family":"Gomes-Gouvea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Catharina S.","family":"Nastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Renato R.","family":"Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flair J.","family":"Carrilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia P.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C\u00e1ssia","family":"Mendes-Corr\u00eaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario G.","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Mazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"1654_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","volume":"394","author":"CW Spearman","year":"2019","unstructured":"Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451\u201366.","journal-title":"Lancet"},{"key":"1654_CR2","doi-asserted-by":"crossref","unstructured":"Benzaken AS, Girade R, Catapan E, et al. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil A mathematical modeling approach. Braz J Infect Dis 2019;23:182\u2013190.","DOI":"10.1016\/j.bjid.2019.04.010"},{"key":"1654_CR3","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","volume":"61","author":"RH Westbrook","year":"2014","unstructured":"Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:S58-68.","journal-title":"J Hepatol"},{"key":"1654_CR4","unstructured":"Minist\u00e9rio da Sa\u00fade do Brasil. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Boletim Epidemiol\u00f3gico de Hepatites Virais - 2020. Brasilia, Brazil, 2020. Available at: http:\/\/www.aids.gov.br\/pt-br\/pub\/2020\/boletim-epidemiologico-hepatites-virais-2020"},{"key":"1654_CR5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/cells8101249","volume":"8","author":"M Khatun","year":"2019","unstructured":"Khatun M, Ray RB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells. 2019;8:1249.","journal-title":"Cells"},{"key":"1654_CR6","unstructured":"Basit H, Tyagi I, Koirala J. Hepatitis C. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020."},{"key":"1654_CR7","first-page":"293","volume":"12","author":"RJ Wong","year":"2016","unstructured":"Wong RJ, Gish RG. Metabolic manifestations and complications associated with chronic Hepatitis C virus infection. Gastroenterol Hepatol (N Y). 2016;12:293\u20139.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"1654_CR8","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/jvh.12930","volume":"25","author":"AC Cardoso","year":"2018","unstructured":"Cardoso AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, Moraes-Coelho HS, Villela-Nogueira CA. Prevalence and predictive factors of moderate\/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP). J Viral Hepat. 2018;25:1244\u201350.","journal-title":"J Viral Hepat"},{"key":"1654_CR9","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461\u20135.","journal-title":"Nat Genet"},{"key":"1654_CR10","doi-asserted-by":"publisher","first-page":"6742","DOI":"10.3748\/wjg.v22.i29.6742","volume":"22","author":"TJ Severson","year":"2016","unstructured":"Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: a systematic clinical review. World J Gastroenterol. 2016;22:6742\u201356.","journal-title":"World J Gastroenterol"},{"key":"1654_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352\u20136.","journal-title":"Nat Genet"},{"key":"1654_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng.2926","volume":"46","author":"OL Holmen","year":"2014","unstructured":"Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet. 2014;46:345\u201351.","journal-title":"Nat Genet"},{"key":"1654_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/hep.27490","volume":"61","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61:506\u201314.","journal-title":"Hepatology"},{"key":"1654_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1053\/j.gastro.2014.11.014","volume":"148","author":"YS Roh","year":"2015","unstructured":"Roh YS, Loomba R, Seki E. The TM6SF2 variants, novel genetic predictors for nonalcoholic steatohepatitis. Gastroenterology. 2015;148:252\u20134.","journal-title":"Gastroenterology"},{"key":"1654_CR15","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/hep.28142","volume":"62","author":"CJ Pirola","year":"2015","unstructured":"Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis. Hepatology. 2015;62:1742\u201356.","journal-title":"Hepatology"},{"key":"1654_CR16","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/liv.12781","volume":"35","author":"N Coppola","year":"2015","unstructured":"Coppola N, Rosa Z, Cirillo G, et al. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. Liver Int. 2015;35:1959\u201363.","journal-title":"Liver Int"},{"key":"1654_CR17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/ijms20061277","volume":"20","author":"V Basyte-Bacevice","year":"2019","unstructured":"Basyte-Bacevice V, Skieceviciene J, Valantiene I, et al. TM6SF2 and MBOAT7 gene variants in liver fibrosis and cirrhosis. Int J Mol Sci. 2019;20:1277.","journal-title":"Int J Mol Sci"},{"key":"1654_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/hep.27811","volume":"62","author":"M Milano","year":"2015","unstructured":"Milano M, Aghemo A, Mancina RM, et al. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology. 2015;62:111\u20137.","journal-title":"Hepatology"},{"key":"1654_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/HMER.S125718","volume":"9","author":"FV Bruschi","year":"2017","unstructured":"Bruschi FV, Tardelli M, Claudel T, Trauner M. PNPLA3 expression and its impact on the liver: current perspectives. Hepat Med. 2017;9:55\u201366.","journal-title":"Hepat Med"},{"key":"1654_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ijc.31910","volume":"144","author":"J Yang","year":"2019","unstructured":"Yang J, Tr\u00e9po E, Nahon P, et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. Int J Cancer. 2019;144:533\u201344.","journal-title":"Int J Cancer"},{"key":"1654_CR21","doi-asserted-by":"crossref","unstructured":"Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ; NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010;52:894\u2013903.","DOI":"10.1002\/hep.23759"},{"key":"1654_CR22","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.aohep.2018.10.004","volume":"18","author":"DF Mazo","year":"2019","unstructured":"Mazo DF, Malta FM, Stefano JT, et al. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Ann Hepatol. 2019;18:466\u201371.","journal-title":"Ann Hepatol"},{"key":"1654_CR23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.4254\/wjh.v12.i10.792","volume":"12","author":"QC Lisboa","year":"2020","unstructured":"Lisboa QC, Nardelli MJ, Pereira PA, et al. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol. 2020;12:792\u2013806.","journal-title":"World J Hepatol"},{"key":"1654_CR24","unstructured":"Crisan D, Grigorescu M, Crisan N, et al. Association between PNPLA3[G]\/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters. J Physiol Pharmacol 2019;70."},{"key":"1654_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/hep.24350","volume":"54","author":"E Tr\u00e9po","year":"2011","unstructured":"Tr\u00e9po E, Pradat P, Potthoff A, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011;54:60\u20139.","journal-title":"Hepatology"},{"key":"1654_CR26","doi-asserted-by":"publisher","first-page":"456","DOI":"10.5009\/gnl15261","volume":"10","author":"JH Fan","year":"2016","unstructured":"Fan JH, Xiang MQ, Li QL, Shi HT, Guo JJ. PNPLA3 rs738409 polymorphism associated with hepatic steatosis and advanced fibrosis in patients with chronic hepatitis C virus: a meta-analysis. Gut Liver. 2016;10:456\u201363.","journal-title":"Gut Liver"},{"key":"1654_CR27","doi-asserted-by":"publisher","first-page":"e0182204","DOI":"10.1371\/journal.pone.0182204","volume":"12","author":"CM Huang","year":"2017","unstructured":"Huang CM, Chang KC, Hung CH, et al. Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. PLoS ONE. 2017;12:e0182204.","journal-title":"PLoS ONE"},{"key":"1654_CR28","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1186\/s12879-017-2887-6","volume":"17","author":"C Manchiero","year":"2017","unstructured":"Manchiero C, Nunes AKDS, Magri MC, et al. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C. BMC Infect Dis. 2017;17:780.","journal-title":"BMC Infect Dis"},{"key":"1654_CR29","doi-asserted-by":"crossref","unstructured":"Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; National Heart, Lung, and Blood Institute; American Heart Association. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24:e13\u20138.","DOI":"10.1161\/01.ATV.0000111245.75752.C6"},{"key":"1654_CR30","doi-asserted-by":"crossref","unstructured":"Vasques AC, Rosado LE, C\u00e1ssia GAlfenas Rd, Geloneze B. Critical analysis on the use of the homeostasis model assessment (HOMA) indexes in the evaluation of the insulin resistance and the pancreatic beta cells functional capacity. Arq Bras Endocrinol Metabol 2008;52:32\u20139.","DOI":"10.1590\/S0004-27302008000100006"},{"key":"1654_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/hep.1840200104","volume":"20","author":"The French METAVIR Cooperative Study Group","year":"1994","unstructured":"The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15\u201320.","journal-title":"Hepatology"},{"key":"1654_CR32","first-page":"314","volume":"32","author":"D Botstein","year":"1980","unstructured":"Botstein D, White RL, Skolnick M, Davis RW. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet. 1980;32:314\u201331.","journal-title":"Am J Hum Genet"},{"key":"1654_CR33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/apt.13169","volume":"41","author":"S Petta","year":"2015","unstructured":"Petta S, Vanni E, Bugianesi E, et al. PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Aliment Pharmacol Ther. 2015;41:939\u201348.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1923\u20131935","key":"1654_CR34","first-page":"e8","volume":"155","author":"A Boyer","year":"2018","unstructured":"Boyer A, Park SB, de Boer YS, Li Q, Liang TJ. TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes. Gastroenterology. 2018;155(1923\u20131935):e8.","journal-title":"Gastroenterology"},{"key":"1654_CR35","doi-asserted-by":"publisher","first-page":"8913","DOI":"10.1073\/pnas.1323785111","volume":"111","author":"H Mahdessian","year":"2014","unstructured":"Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA. 2014;111:8913\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1654_CR36","doi-asserted-by":"publisher","first-page":"9273","DOI":"10.1038\/s41598-017-09548-9","volume":"7","author":"Z Liu","year":"2017","unstructured":"Liu Z, Que S, Zhou L, et al. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis. Sci Rep. 2017;7:9273.","journal-title":"Sci Rep"},{"key":"1654_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/hep.28475","volume":"64","author":"M Eslam","year":"2016","unstructured":"Eslam M, Mangia A, Berg T, et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016;64:34\u201346.","journal-title":"Hepatology"},{"key":"1654_CR38","doi-asserted-by":"publisher","first-page":"115025","DOI":"10.1016\/j.diagmicrobio.2020.115025","volume":"97","author":"MC Magri","year":"2020","unstructured":"Magri MC, Manchiero C, Prata TVG, et al. The influence of gene-chronic hepatitis C virus infection on hepatic fibrosis and steatosis. Diagn Microbiol Infect Dis. 2020;97:115025.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1654_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2010.12.020","volume":"55","author":"T Cai","year":"2011","unstructured":"Cai T, Dufour JF, Muellhaupt B, et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol. 2011;55:529\u201335.","journal-title":"J Hepatol"},{"key":"1654_CR40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/hep.24123","volume":"53","author":"L Valenti","year":"2011","unstructured":"Valenti L, Rumi M, Galmozzi E, et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53:791\u20139.","journal-title":"Hepatology"},{"key":"1654_CR41","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.4254\/wjh.v8.i35.1584","volume":"8","author":"H Salameh","year":"2016","unstructured":"Salameh H, Masadeh M, Al Hanayneh M, et al. PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease. World J Hepatol. 2016;8:1584\u201392.","journal-title":"World J Hepatol"},{"key":"1654_CR42","doi-asserted-by":"publisher","first-page":"e81312","DOI":"10.1371\/journal.pone.0081312","volume":"8","author":"M Nakamura","year":"2013","unstructured":"Nakamura M, Kanda T, Nakamoto S, et al. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. PLoS ONE. 2013;8:e81312.","journal-title":"PLoS ONE"},{"key":"1654_CR43","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.numecd.2019.06.002","volume":"29","author":"CM Machado","year":"2019","unstructured":"Machado CM, Leite NC, Fran\u00e7a PH, Cardoso CR, Salles GF, Villela-Nogueira CA. PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease? Nutr Metab Cardiovasc Dis. 2019;29:965\u201371.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1654_CR44","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2217\/pgs.15.65","volume":"16","author":"K Rembeck","year":"2015","unstructured":"Rembeck K, Lagging M. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics. 2015;16:1179\u201388.","journal-title":"Pharmacogenomics"},{"key":"1654_CR45","doi-asserted-by":"publisher","first-page":"e000241","DOI":"10.1136\/bmjgast-2018-000241","volume":"6","author":"W Dunn","year":"2019","unstructured":"Dunn W, Vittal A, Zhao J, et al. PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis. BMJ Open Gastroenterol. 2019;6:e000241.","journal-title":"BMJ Open Gastroenterol"},{"key":"1654_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40794-016-0038-5","volume":"2","author":"HL Stevenson","year":"2016","unstructured":"Stevenson HL, Utay NS. Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era. Trop Dis Travel Med Vaccines. 2016;2:21.","journal-title":"Trop Dis Travel Med Vaccines"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01654-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-021-01654-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01654-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T11:17:04Z","timestamp":1614079024000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01654-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1654"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01654-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of the Hospital das Clinicas of the University of Sao Paulo School of Medicine has approved this study (numbered 1,531,382 and 2,676,105). The protocol followed the 1975 Declaration of Helsinki. Informed consent was obtained from participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}